Correvio Pharma Corp.

Advanz Pharma has agreed a deal worth around $76m to swallow up debt-ridden, acute care specialist Correvio Pharma , which the firm says will provide a direct commercial presence in major European m

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Hoth, Voltron Form JV To Dev

Who: Advanz Pharma/Correvio Pharma (formerly Cardiome) What: Advanz will purchase troubled Correvio for an expected $76m in cash, nearly two-thirds of which will be used to pay off Correvio’s outst

Basilea Pharmaceutica Ltd. ’s fibroblast growth factor receptor (FGFR) kinase inhibitor, derazantinib, also acts as an inhibitor at the colony-stimulating factor-1 receptor (CSF1R), and this activity